遼寧成大(600739.SH)擬分拆成大生物至上交所科創板上市
格隆匯4月2日丨遼寧成大(600739.SH)公佈,公司擬將其控股子公司成大生物分拆至上交所科創板上市。本次分拆完成後,遼寧成大股權結構不會發生變化且仍擁有對成大生物的控股權。
本次發行均為新股,不涉及股東公開發售股份。本次發行不超過4165萬股(含4165萬股,且不低於本次發行後成大生物總股本的10%)。若安排超額配售,超額配售部分不超過本次發行股票數量的15%,即超額配售部分不超過624.75萬股(含6,247,500股)。
公司業務涵蓋了生物製品、醫藥流通、醫療服務、金融投資、供應鏈服務(貿易)和能源開發等業務,各業務發展良好。其中生物製品業務由子公司成大生物負責開展,主要從事人用疫苗的研發、生產和銷售工作。成大生物與公司其他業務板塊保持較高的獨立性,公司本次分拆不會對其他業務板塊持續經營構成實質性影響。
通過本次分拆,可使遼寧成大和成大生物的主業結構更加清晰,成大生物將依託上交所科創板平台獨立融資,促進自身生物製品業務的發展。本次分拆有利於進一步提升公司整體市值,增強公司及所屬子公司的盈利能力和綜合競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.